New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
10:28 EDTEBKDY, VSTM, ZINC, ZBRA, TFM, HOS, VRTX, KPTI, BRKR, BECNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Beacon Roofing (BECN) downgraded to Market Perform from Outperform at William Blair... Bruker (BRKR) downgraded to Neutral from Buy at ISI Group... Erste Group Bank (EBKDY) downgraded to Hold from Buy at Deutsche Bank... Hornbeck Offshore (HOS) downgraded to Equal Weight from Overweight at Stephens... Horsehead Holding (ZINC) downgraded to Market Perform at FBR Capital... Karyopharm (KPTI) downgraded to Perform from Outperform at Oppenheimer... The Fresh Market (TFM) downgraded to Sell from Neutral at Goldman... Verastem (VSTM) downgraded to Perform from Outperform at Oppenheimer... Vertex (VRTX) downgraded to Perform from Outperform at Oppenheimer... Zebra Technologies (ZBRA) downgraded to In-Line from Outperform at Imperial Capital.
News For BECN;BRKR;EBKDY;HOS;ZINC;KPTI;TFM;VSTM;VRTX;ZBRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 16, 2014
12:33 EDTVSTMVerastem initiated with an Outperform at Wells Fargo
Subscribe for More Information
07:30 EDTVSTMGuggenheim to hold a conference
Subscribe for More Information
December 15, 2014
14:03 EDTBRKRBruker comments on SEC findings, confirms $2.4M settlement
Bruker said in a filing that on December 15, Bruker Corporation resolved the investigation of the SEC into the company’s possible violations of the Foreign Corrupt Practices Act arising from past conduct of the company’s subsidiaries operating in China. In August 2011, as disclosed since that time in periodic reports filed with the SEC, Bruker made a voluntary disclosure to the United States DOJ and the SEC of the results of an investigation by the Audit Committee of its Board of Directors regarding these matters and it has have cooperated with the DOJ and SEC in connection with their investigations. Effective December 15, the company consented to the entry of an administrative cease-and-desist order by the SEC concerning violations of the books and records and internal controls provisions of the FCPA. Pursuant to the Order, Bruker will pay an aggregate amount of approximately $2.4M, consisting of $1,714,852 in disgorgement, $310,117 in prejudgment interest, and a $375,000 penalty. The amounts to be paid by the company was fully accrued as of September 30. The company consented to the Order without admitting or denying the SEC findings. In the Order, the SEC recognized the company’s “extensive, thorough, and real-time cooperation with the Commission.” Further, the Order notes that in determining the settlement amount, the SEC considered “remedial acts promptly undertaken by Bruker and the significant cooperation it afforded to the Commission staff.”
13:29 EDTBRKRBruker to pay approximately $2.4M to settle SEC charges of FCPA violations
Subscribe for More Information
10:18 EDTKPTIKaryopharm management to meet with JMP Securities
Subscribe for More Information
09:06 EDTVRTXVertex names David Altshuler as Chief Scientific Officer
Subscribe for More Information
December 12, 2014
15:32 EDTTFMStephens consumer analysts hold an analyst/industry conference call
Subscribe for More Information
08:16 EDTKPTIKaryopharm sell-off overdone, says JMP Securities
Subscribe for More Information
08:01 EDTVRTXPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 11, 2014
16:30 EDTKPTIOn The Fly: Closing Wrap
Subscribe for More Information
08:10 EDTKPTIKaryopharm initiates third registration-directed clinical trial of Selinexor
Karyopharm Therapeutics announced the initiation of the SADAL study, or Selinexor and Dexamethasone in Aggressive Lymphoma, a registration-directed, Phase 2b study of Selinexor, or KPT-330, in patients with relapsed/refractory diffuse large B-cell lymphoma, or DLBCL. This randomized, multi-center study of Selinexor, one of the company's novel, oral Selective Inhibitor of Nuclear Export/SINE compounds, is being evaluated as a single agent in combination with dexamethasone for supportive care and is expected to enroll approximately 200 patients in approximately 90 sites worldwide. Karyopharm has received Orphan Drug Designation from the FDA and European Medicines Agency, or EMA, for Selinexor for the treatment of patients with DLBCL. This open-label Phase 2b study will evaluate the safety and efficacy of high dose versus mid dose Selinexor in combination with low dose dexamethasone for supportive care, each given orally to approximately 200 patients with relapsed/refractory DLBCL. Overall response rate, or ORR, is the primary endpoint. The study is expected to take approximately two years to complete and is intended to support accelerated regulatory approval. This study was designed in consultation with the FDA and on the basis of data from Karyopharm's ongoing Phase 1 study of Selinexor in patients with advanced hematologic malignancies.
07:28 EDTVRTXCBI to hold a summit
2nd Specialty Data Optimization Summit is being held in Philadelphia on December 11.
December 10, 2014
10:10 EDTZINCHigh option volume stocks
Subscribe for More Information
09:05 EDTZBRAZebra Technologies announces executive appointments
Subscribe for More Information
08:18 EDTTFMDeutsche Bank to hold a conference
Subscribe for More Information
07:24 EDTZBRAImperial Capital to hold a conference
Subscribe for More Information
December 9, 2014
12:30 EDTHOSWells Fargo to hold a symposium
Subscribe for More Information
10:19 EDTKPTIHigh option volume stocks
Subscribe for More Information
10:08 EDTKPTIHigh option volume stocks
Subscribe for More Information
December 8, 2014
13:03 EDTKPTIKaryopharm reports positive combination data for Selinexor
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use